Literature DB >> 18256684

A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease.

P G Maslak, T Dao, M Gomez, S Chanel, J Packin, T Korontsvit, V Zakhaleva, J Pinilla-Ibarz, E Berman, D A Scheinberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18256684     DOI： 10.1038/leu.2008.7

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  18 in total

Review 1.  Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review.

Authors:  Eva van Doorn; Heng Liu; Anke Huckriede; Eelko Hak
Journal:  Hum Vaccin Immunother       Date:  2015-09-17       Impact factor: 3.452

Review 2.  Peptide vaccine therapy for leukemia.

Authors:  K Rezvani
Journal:  Int J Hematol       Date:  2011-03-08       Impact factor: 2.490

3.  EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.

Authors:  Christopher H Evans; Fangjun Liu; Ryan M Porter; Regina P O'Sullivan; Taha Merghoub; Elaine P Lunsford; Kyle Robichaud; Frans Van Valen; Stephen L Lessnick; Mark C Gebhardt; James W Wells
Journal:  Clin Cancer Res       Date:  2012-08-09       Impact factor: 12.531

Review 4.  Peptide vaccines for hematological malignancies: a missed promise?

Authors:  Monica Bocchia; Marzia Defina; Lara Aprile; Anna Sicuranza
Journal:  Int J Hematol       Date:  2014-01-08       Impact factor: 2.490

5.  An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.

Authors:  Nicola Hardwick; Sarah Buchan; Wendy Ingram; Ghazala Khan; Gisella Vittes; Jason Rice; Karen Pulford; Ghulam Mufti; Freda Stevenson; Barbara-ann Guinn
Journal:  Cancer Immun       Date:  2013-07-15

Review 6.  Vaccination strategies in lymphomas and leukaemias: recent progress.

Authors:  Katayoun Rezvani; Hugues de Lavallade
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

7.  WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase.

Authors:  Miwako Narita; Masayoshi Masuko; Tohri Kurasaki; Toshiki Kitajima; Shoko Takenouchi; Anri Saitoh; Norihiro Watanabe; Tatsuo Furukawa; Ken Toba; Ichiro Fuse; Yoshifusa Aizawa; Manabu Kawakami; Yoshihiro Oka; Haruo Sugiyama; Masuhiro Takahashi
Journal:  Int J Med Sci       Date:  2010-04-20       Impact factor: 3.738

Review 8.  Modern approaches to treating chronic myelogenous leukemia.

Authors:  Javier Pinilla-Ibarz; Celeste Bello
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

9.  Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.

Authors:  Nitin Jain; James M Reuben; Hagop Kantarjian; Changping Li; Hui Gao; Bang-Ning Lee; Evan N Cohen; Theresa Ebarb; David A Scheinberg; Jorge Cortes
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

10.  Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

Authors:  Peter G Maslak; Tao Dao; Yvette Bernal; Suzanne M Chanel; Rong Zhang; Mark Frattini; Todd Rosenblat; Joseph G Jurcic; Renier J Brentjens; Maria E Arcila; Raajit Rampal; Jae H Park; Dan Douer; Laura Katz; Nicholas Sarlis; Martin S Tallman; David A Scheinberg
Journal:  Blood Adv       Date:  2018-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.